NCI National Clinical Trials Network

EA9213

ECOG-ACRIN cancer research group

For Patients with T Cell Acute Lymphoblastic Leukemia

EA9213 Available Through ECOG-ACRIN Cancer Research Group

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

Patient Population

See Section 3.0 for Complete Eligibility Details

Preregistration- Step 0 (must be able to undergo diagnostic bone marrow aspirate following preregistration if not performed previously):

- Age ≥ 18 years
- Must have documented T cell ALL and must be in first or later hematologic CR/CRi after a minimum of 2 blocks of intensive chemotherapy (patients ≥ 65 years of age that are judged unfit for 2 blocks may enroll after one cycle of chemotherapy as long as they are in CR/CRi at least 28 days after initiation of leukemia directed therapy [see protocol for details])

Registration- Step 1:

- Patients in hematologic CR/CRi must have persistent/recurrent MRD ≥ 10^{-4} (confirmed by flow cytometry)
- Patients may have undergone prior allogeneic stem cell transplant, but may not have GVHD that requires ongoing immunosuppressive therapy
- ECOG PS 0-2, adequate lab values
- HIV, HBV, HCV patients are eligible per protocol
- No active CNS involvement at time of Step 1 registration (prior CNS involvement is permitted)
- Patients with a prior/concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety/efficacy assessment of the investigational regimen are eligible
- Patients with known history/current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should be NYHA class 2B or better

Treatment Plan

See Section 5.0 for Complete Treatment Details

- All patients will receive daratumumab-hyaluronidase once weekly for up to 4 doses during Course 1
- Bone marrow biopsy will be done on Day 29
- MRD negative patients (Day 29) may receive an additional 4 weekly doses of daratumumab-hyaluronidase during Course 1B (for 8 total doses)
- MRD positive patients may receive an additional 4 weekly doses of daratumumab-hyaluronidase in combination with chemotherapy during Course IA (for 8 total doses)
  - ◊ Chemotherapy to include physician's choice of HyperCVAD part B with high dose cytarabine and methotrexate or Capizzi methotrexate
- A bone marrow biopsy will be repeated on Day 64 or on count recovery to assess response
- If counts do not recover by Day 84 a bone marrow MRD assessment should be performed
- MRD negative patients can:
  - ◊ Undergo allogeneic stem cell transplant at the treating physician's discretion (but they may not receive additional daratumumab)
  - ◊ Receive donor lymphocyte infusion and remain on treatment with daratumumab
  - ◊ If no transplant, proceed to Course 2 with daratumumab-hyaluronidase once every 2 weeks for 8 doses
- Responding patients will undergo surveillance bone marrow biopsies with MRD assessment performed as per local standards
- MRD positive patients on Day 64 will come off study

NOTE:

- *Prophylaxis/treatment with intrathecal chemotherapy for central nervous system ALL is at the physician's discretion and is allowed during daratumumab-hyaluronidase cycles*
- *Administer pre– and post-medications per protocol*

Study Chair:
Shira Dinner, MD

Co-Chair:
Talha Badar, MD

Patient Enrollment

All Sites: Oncology Patient Enrollment Network (OPEN) https://open.ctsu.org

Protocol Information

ECOG-ACRIN Operations-Boston: 857-504-2900, http://ecog-acrin.org (Member Login)

Please Enroll Your Eligible Patients!

Version 03/11/22

EA9213

Schema



Accrual = 20

1. Refer to Section 5.1.2 for details on Methotrexate-based chemotherapy.
2. Refer to Section 10 for more information.
3. Patients with a complete MRD response on treatment can undergo allogeneic stem cell transplant at any time after Course 1 or Course 2 at the treating physician's discretion. Patients with morphologic evidence of T-ALL in the bone marrow with ≥ 5% blasts will be taken off study treatment.